Related Experiment Video
Updated: Sep 13, 2025

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
Meropenem/Vaborbactam in Pediatrics: 2 Cases of CRE Intraabdominal Infection
Ugene Sano1, Rachel Meyers1,2, Uzma Hasan1
1Departments of Pharmacy (US, RM, SS) and Pediatric Infectious Disease (UH), Cooperman Barnabas Medical Center, Livingston, NJ.
Abstract:
Meropenem/vaborbactam is a combination antibiotic with a carbapenem and a carbapenemase inhibitor typically reserved for extensively drug-resistant bacterial infections, such as carbapenem-resistant Enterobacterales (CRE). Meropenem/vaborbactam is approved by the United States Food and Drug Administration for use in adults for complicated urinary tract infections, whereas data in the pediatric population are limited. This case series described the use of meropenem/vaborbactam in 2 pediatric patients, ages 11 and 15, with intraabdominal abscesses from CRE. Both patients had clinically improved after the initiation of meropenem/vaborbactam and reported no complications during their follow-up appointments after the completion of their antibiotic courses. These cases demonstrate the safe and effective use of meropenem/vaborbactam in these 2 pediatric patients. Although meropenem/vaborbactam successfully treated both patients' infections, additional data are needed in this population to determine the safety profile and optimal use for pediatric patients.
Insights
Meropenem/vaborbactam showed safe and effective use in two pediatric patients with carbapenem-resistant Enterobacterales (CRE) intraabdominal abscesses. Further research is needed to establish optimal use and safety in pediatric populations.
Area of Science:
- Infectious Diseases
- Pediatric Pharmacology
- Antimicrobial Resistance
Background:
- Meropenem/vaborbactam is an antibiotic combination for extensively drug-resistant infections.
- Approved for adult complicated urinary tract infections, pediatric data are limited.
- Carbapenem-resistant Enterobacterales (CRE) pose a significant treatment challenge.
Purpose of the Study:
- To describe the use of meropenem/vaborbactam in pediatric patients with CRE infections.
- To evaluate the safety and efficacy of meropenem/vaborbactam in this population.
Main Methods:
- Case series involving two pediatric patients (ages 11 and 15).
- Patients presented with intraabdominal abscesses caused by CRE.
- Treatment involved meropenem/vaborbactam administration.
Main Results:
- Both pediatric patients experienced clinical improvement.
- No complications were reported during follow-up after antibiotic course completion.
- Meropenem/vaborbactam demonstrated safe and effective treatment in these cases.
Conclusions:
- Meropenem/vaborbactam can be safely and effectively used in pediatric patients for CRE infections.
- Additional data are required to determine the optimal use and safety profile in pediatric populations.
More Related Videos
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Pyelonephritis I: Introduction
Urinary Tract Infection IV: Nursing Management
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

